Overview

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Status:
NOT_YET_RECRUITING

Trial end date:
2033-11-18

Target enrollment:

Participant gender:

Summary

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

Phase:

PHASE2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Carboplatin
Cisplatin
Gemcitabine